 Artist: No Fun At All: mp3 download Genre(s): Rock: Punk-Rock No Fun At All's discography:  State of Flow Year: 2003 Tracks: 12  Master Celebrations Year: 2003 Tracks: 24  Throw It In Year: 1997 Tracks: 17  The Big Knockover Year: 1997 Tracks: 15  No Straight Angles Year: Tracks: 15  EP's Going Steady Year: Tracks: 25 The Swedish hardcore ring No Fun at All formed in the small town of Skinnskatteberg during the summertime of 1991; light-emitting crystal rectifier by songwriter/guitarist Mikael Danielsson, the original lineup too included singer/drummer Jimmie Ohlsson and bassist Henrik Sunvisson. After completing the group's 1993 debut, Vision, Ohlsson exited to focus his wide-cut energies on his other band, Sober; with new frontman Ingemar Jansson, lead guitarist Krister Johansson, and drummer Kjell Ramstedt, No Fun at All returned in 1994 with No Straight Angles, followed a year by and by by Out of Bounds. In the rouse of 1997's The Big Knockover, Sunvisson throw in the towel the radical, with Danielsson assumptive bass duties; new second guitarist Stefan Neuman was installed in meter for 1999's Resilient in Tokyo. State of Flow followed in 2000, but it proved to be the band's final studio album. In 2003, NFAA's Swedish label, Burning Heart, united with American punk rocker stalwart Epitaph to release Master Celebrations, a fan-picked 24-track retrospective spanning the band's career. |
Saturday, 30 August 2008
Mp3 music: No Fun At All
Wednesday, 20 August 2008
Mental Health Issues Prominent In Child Soldiers
�
Compared to children in Nepal wHO were not forced into military
service, former child soldiers were more likely to present severe
mental health problems such as symptoms of posttraumatic stress
disorder (PTSD) and depression. These findings are reported in the
August 13 issue of JAMA.
As children continue to be ill-used by armed groups all over the
world, special mental wellness interventions for child soldiers are ever so
more necessary. There is, however, a paucity of research that
is consecrate to perusal the mental health of child soldiers in armed
conflicts. For several reasons, civilian children are more accessible
than child soldiers.
Researcher Brandon A. Kohrt (Emory University, Atlanta) and colleagues
set extinct to determine the mental health effects of both child soldiers
and children who were never strained into military service. The sample
consisted of 141 former baby soldiers and 141 never-conscripted
children in Nepal between March and April 2007. The children were
matched on historic period, sex, education Department, and ethnicity, and all participants
experient at least 1 type of trauma. The quondam child soldiers were
'tween 5 and 16 years old at time of conscription, and the modal age
of study participants was about 15.75 years old at the time of the
study.
Kohrt and colleagues set up that 75 of the child soldiers (52.3%) met
the symptom cutoff score for depression, 65 (46.1%) met the score for
anxiety, 78 (55.3%) met the criteria for PTSD, 55 (39%) met
the criteria for general psychological difficulties, and 88 (62.4%)
were functionally impaired. Statistically adjusting for traumatic
exposures and other possibly contradictory variables held that beingness a
child soldier was significantly associated with depression and PTSD
among girls (2.4 and 6.8 times higher odds, respectively) and PTSD
among boys (3.8 times higher betting odds). However, in that location was no statistical
connexion between beingness a baby soldier and general psychological
difficulties, anxiousness, or use impairment.
The authors note that, "The difference in mental health outcomes
between child soldiers and never-conscripted children can be explained
in part by greater exposure to traumatic events among child soldiers,
especially for general psychological difficulties and function
impairment."
"The study has several clinical and programmatic implications. First,
the greater burden of mental health problems among former child
soldiers supports the motive for focused programming, which should
include, but non consist entirely of, interventions to concentrate depression
symptoms and the psychological sequelae of psychic trauma, especially bombings
and torturing, as advantageously as incorporate belongingness and income
generation. Second, girl soldiers crataegus laevigata require focused attention,
perchance for factors not addressed in this study, such as problems of
sexual violence and reintegration difficulties. Third, the variation in
type and severity of mental health problems highlights the importance
of showing, including topically developed measures of function
impairment, as a base for intercession," suggest the researchers.
They reason: "Without screening there is a risk of infection of pathologizing
child soldiers as a group quite than providing support to those
individuals most impaired. Finally, the presence of mental health
problems among never-conscripted children illustrates the need for
comprehensive postconflict community-based psychosocial care non
restricted exclusively to child soldiers."
The Comparison of Mental Health Between Former Child Soldiers
and Children Never Conscripted by Armed Groups in Nepal
Brandon A. Kohrt, MA; Mark J. D. Jordans, MA; Wietse A. Tol,
MA; Rebecca A. Speckman, BA; Sujen M. Maharjan, BA; Carol M. Worthman,
PhD; Ivan H. Komproe, PhD
JAMA(2008).
300[6]: pp. 691-702.
Click
Here to View Abstract
Written by: Peter M Crosta
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
More info
Compared to children in Nepal wHO were not forced into military
service, former child soldiers were more likely to present severe
mental health problems such as symptoms of posttraumatic stress
disorder (PTSD) and depression. These findings are reported in the
August 13 issue of JAMA.
As children continue to be ill-used by armed groups all over the
world, special mental wellness interventions for child soldiers are ever so
more necessary. There is, however, a paucity of research that
is consecrate to perusal the mental health of child soldiers in armed
conflicts. For several reasons, civilian children are more accessible
than child soldiers.
Researcher Brandon A. Kohrt (Emory University, Atlanta) and colleagues
set extinct to determine the mental health effects of both child soldiers
and children who were never strained into military service. The sample
consisted of 141 former baby soldiers and 141 never-conscripted
children in Nepal between March and April 2007. The children were
matched on historic period, sex, education Department, and ethnicity, and all participants
experient at least 1 type of trauma. The quondam child soldiers were
'tween 5 and 16 years old at time of conscription, and the modal age
of study participants was about 15.75 years old at the time of the
study.
Kohrt and colleagues set up that 75 of the child soldiers (52.3%) met
the symptom cutoff score for depression, 65 (46.1%) met the score for
anxiety, 78 (55.3%) met the criteria for PTSD, 55 (39%) met
the criteria for general psychological difficulties, and 88 (62.4%)
were functionally impaired. Statistically adjusting for traumatic
exposures and other possibly contradictory variables held that beingness a
child soldier was significantly associated with depression and PTSD
among girls (2.4 and 6.8 times higher odds, respectively) and PTSD
among boys (3.8 times higher betting odds). However, in that location was no statistical
connexion between beingness a baby soldier and general psychological
difficulties, anxiousness, or use impairment.
The authors note that, "The difference in mental health outcomes
between child soldiers and never-conscripted children can be explained
in part by greater exposure to traumatic events among child soldiers,
especially for general psychological difficulties and function
impairment."
"The study has several clinical and programmatic implications. First,
the greater burden of mental health problems among former child
soldiers supports the motive for focused programming, which should
include, but non consist entirely of, interventions to concentrate depression
symptoms and the psychological sequelae of psychic trauma, especially bombings
and torturing, as advantageously as incorporate belongingness and income
generation. Second, girl soldiers crataegus laevigata require focused attention,
perchance for factors not addressed in this study, such as problems of
sexual violence and reintegration difficulties. Third, the variation in
type and severity of mental health problems highlights the importance
of showing, including topically developed measures of function
impairment, as a base for intercession," suggest the researchers.
They reason: "Without screening there is a risk of infection of pathologizing
child soldiers as a group quite than providing support to those
individuals most impaired. Finally, the presence of mental health
problems among never-conscripted children illustrates the need for
comprehensive postconflict community-based psychosocial care non
restricted exclusively to child soldiers."
The Comparison of Mental Health Between Former Child Soldiers
and Children Never Conscripted by Armed Groups in Nepal
Brandon A. Kohrt, MA; Mark J. D. Jordans, MA; Wietse A. Tol,
MA; Rebecca A. Speckman, BA; Sujen M. Maharjan, BA; Carol M. Worthman,
PhD; Ivan H. Komproe, PhD
JAMA(2008).
300[6]: pp. 691-702.
Click
Here to View Abstract
Written by: Peter M Crosta
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
More info
Sunday, 10 August 2008
ARIAD Announces Start Of Phase 2 Clinical Study Of Oral Deforolimus In Patients With Advanced Endometrial Cancer
�ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) proclaimed the origination of a randomized, multi-center, Phase 2 clinical trial to valuate the safety and efficaciousness of unwritten deforolimus, its investigational mTOR inhibitor, in patients with advanced endometrial cancer. In collaboration with Merck & Co. Inc., deforolimus is currently being studied in multiple clinical trials, both alone and in combination with other therapies, in patients with several different types of cancer. Under terms of the agreement, ARIAD will receive a $2.5 million milestone payment from Merck upon treating the first patient in this clinical study.
The clinical trial will compare single-agent oral deforolimus to progestin in patients with metastatic or repeated endometrial cancer following first line chemotherapy. The primary endpoint for the study is progression-free survival. Overall survival and response rate will be evaluated as secondary endpoints. This is the second Phase 2 clinical trial to begin this quarter examining the safety and efficacy of oral deforolimus in patients with different solid tumors.
"We make Phase 2 data on the endovenous form of deforolimus in endometrial crab and are pleased to now prove the potential difference of this drug prospect in its oral shape in alike patients with this crab," stated Pierre F. Dodion, senior vice president and chief medical officer of ARIAD. "There is substantial unmet aesculapian need for the efficacious treatment of patients with endometrial crab, and this controlled clinical study is designed to help inform us of the potentiality impact of oral deforolimus on patients with this difficult-to-treat crab."
The clinical trial will enroll 150 patients at approximately 50 sites including medical centers in North America, Europe, Asia and Australia. Patients will be randomized (1:1) to oral deforolimus or progestin, a usually accepted treatment in patients with endometrial cancer. Enrollment in the trial is expected to be completed by the second half of 2009.
"With the start of this trial, we today have begun enrollment in two Phase 2 clinical trials of oral deforolimus this quarter," said Harvey J. Berger, M.D., chair and headman executive ship's officer of ARIAD. "The begin of this study is another important milestone for deforolimus and for the joint development program with Merck. We are committed to complemental these clinical trials as quickly as possible facilitating the voltage development of deforolimus in multiple cancer indications."
ARIAD announced the initiation last month of a Phase 2 clinical trial of deforolimus in patients with advanced breast cancer.
For more selective information about clinical trials evaluating deforolimus, or to feel a trial site close to you, patients and physicians should call the US toll-free number 1-877-621-2302 or the international identification number 1-617-621-2302, or email us at ClinicalTrials@ariad.com. Additional information can also be launch at www.ClinicalTrials.gov.
About Endometrial Cancer
Endometrial cancer, which develops from the interior lining of the uterus, is the most coarse cancer found in the female reproductive system.
According to the American Cancer Society, about 40,one C new cases of endometrial cancer will be diagnosed in the United States and close to 7,470 women will die from this disease in 2008. Prognosis for patients is primarily based on the time of diagnosis relation to the stage of the cancer. Initial discourse consists of surgery alone, or in combination with radiation, chemotherapy and/or hormonal therapy. For those women with disease progression, chemotherapy is the only currently available treatment option, and limited benefit has been seen in such cases, emphasizing the need for new therapies.
About Deforolimus
ARIAD's lead product prospect, deforolimus, is a novel rapamycin analogue that specifically and potently inhibits mTOR, a downstream activator of the PI3K/Akt and food sensing pathways. The mTOR protein acts of the Apostles as a "master switch" in crab cells. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, part, metabolism, and angiogenesis. Multiple Phase 1 and 2 clinical trials of deforolimus in solid tumors and hematologic cancers have completed patient enrollment. The global Phase 3 SUCCEED trial of oral deforolimus in metastatic soft-tissue and bone sarcomas is based on a Special Protocol Assessment agreed upon by the U.S. Food and Drug Administration. ARIAD has a global partnership with Merck & Co., Inc. to develop and commercialize deforolimus, an investigational mTOR inhibitor, in patients with malignant neoplastic disease.
About ARIAD
ARIAD is engaged in the uncovering and evolution of breakthrough medicines to treat crab by regulating cell sign with small molecules. ARIAD is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. ARIAD has a worldwide partnership with Merck & Co., Inc. to develop and commercialize deforolimus, ARIAD's lead cancer product nominee, which is in Phase 3 clinical development. ARIAD's second oncology product candidate, oral AP24534, is a novel multi-targeted kinase inhibitor in Phase 1 clinical development in hematological cancers. ARIAD has an single license to pioneering technology and patents related to certain NF-?B treatment methods, and the discovery and development of drugs to regulate NF-?B cell-signaling natural action, which may be useful in treating certain diseases. Additional information about ARIAD can be found on the web at hypertext transfer protocol://www.ariad.com.
This press spillage contains "innovative statements." Forward-looking statements are based on management's expectations and ar subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and public presentation to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, the costs associated with our research, development, manufacturing and other activities, the deal and results of preclinical and clinical studies of our product candidates, difficulties or delays in obtaining regulatory approvals to market place products resulting from our development efforts, our trust on our strategic partners and licensees and other key parties for the successful evolution, manufacturing and commercialization of products, the adequacy of our working capital resources and the availableness of additional funding, patent protection and third-party intellectual property claims relating to our and any partner's product candidates, the timing, scope, cost and outcome of legal and patent office proceeding concerning our NF-?B patent portfolio, the potential attainment of or other strategic transaction regarding the minority stockholders' interests in our 80%-owned underling, ARIAD Gene Therapeutics, Inc., future capital needs, risks related to key employees, markets, economical conditions, prices, reimbursement rates and competition, and other factors elaborate in the Company's public filings with the U.S. Securities and Exchange Commission. The selective information contained in this iron out release is believed to be stream as of the date of original issue. The Company does not signify to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as compulsory by law.
http://www.ariad.com
More info
The clinical trial will compare single-agent oral deforolimus to progestin in patients with metastatic or repeated endometrial cancer following first line chemotherapy. The primary endpoint for the study is progression-free survival. Overall survival and response rate will be evaluated as secondary endpoints. This is the second Phase 2 clinical trial to begin this quarter examining the safety and efficacy of oral deforolimus in patients with different solid tumors.
"We make Phase 2 data on the endovenous form of deforolimus in endometrial crab and are pleased to now prove the potential difference of this drug prospect in its oral shape in alike patients with this crab," stated Pierre F. Dodion, senior vice president and chief medical officer of ARIAD. "There is substantial unmet aesculapian need for the efficacious treatment of patients with endometrial crab, and this controlled clinical study is designed to help inform us of the potentiality impact of oral deforolimus on patients with this difficult-to-treat crab."
The clinical trial will enroll 150 patients at approximately 50 sites including medical centers in North America, Europe, Asia and Australia. Patients will be randomized (1:1) to oral deforolimus or progestin, a usually accepted treatment in patients with endometrial cancer. Enrollment in the trial is expected to be completed by the second half of 2009.
"With the start of this trial, we today have begun enrollment in two Phase 2 clinical trials of oral deforolimus this quarter," said Harvey J. Berger, M.D., chair and headman executive ship's officer of ARIAD. "The begin of this study is another important milestone for deforolimus and for the joint development program with Merck. We are committed to complemental these clinical trials as quickly as possible facilitating the voltage development of deforolimus in multiple cancer indications."
ARIAD announced the initiation last month of a Phase 2 clinical trial of deforolimus in patients with advanced breast cancer.
For more selective information about clinical trials evaluating deforolimus, or to feel a trial site close to you, patients and physicians should call the US toll-free number 1-877-621-2302 or the international identification number 1-617-621-2302, or email us at ClinicalTrials@ariad.com. Additional information can also be launch at www.ClinicalTrials.gov.
About Endometrial Cancer
Endometrial cancer, which develops from the interior lining of the uterus, is the most coarse cancer found in the female reproductive system.
According to the American Cancer Society, about 40,one C new cases of endometrial cancer will be diagnosed in the United States and close to 7,470 women will die from this disease in 2008. Prognosis for patients is primarily based on the time of diagnosis relation to the stage of the cancer. Initial discourse consists of surgery alone, or in combination with radiation, chemotherapy and/or hormonal therapy. For those women with disease progression, chemotherapy is the only currently available treatment option, and limited benefit has been seen in such cases, emphasizing the need for new therapies.
About Deforolimus
ARIAD's lead product prospect, deforolimus, is a novel rapamycin analogue that specifically and potently inhibits mTOR, a downstream activator of the PI3K/Akt and food sensing pathways. The mTOR protein acts of the Apostles as a "master switch" in crab cells. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, part, metabolism, and angiogenesis. Multiple Phase 1 and 2 clinical trials of deforolimus in solid tumors and hematologic cancers have completed patient enrollment. The global Phase 3 SUCCEED trial of oral deforolimus in metastatic soft-tissue and bone sarcomas is based on a Special Protocol Assessment agreed upon by the U.S. Food and Drug Administration. ARIAD has a global partnership with Merck & Co., Inc. to develop and commercialize deforolimus, an investigational mTOR inhibitor, in patients with malignant neoplastic disease.
About ARIAD
ARIAD is engaged in the uncovering and evolution of breakthrough medicines to treat crab by regulating cell sign with small molecules. ARIAD is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. ARIAD has a worldwide partnership with Merck & Co., Inc. to develop and commercialize deforolimus, ARIAD's lead cancer product nominee, which is in Phase 3 clinical development. ARIAD's second oncology product candidate, oral AP24534, is a novel multi-targeted kinase inhibitor in Phase 1 clinical development in hematological cancers. ARIAD has an single license to pioneering technology and patents related to certain NF-?B treatment methods, and the discovery and development of drugs to regulate NF-?B cell-signaling natural action, which may be useful in treating certain diseases. Additional information about ARIAD can be found on the web at hypertext transfer protocol://www.ariad.com.
This press spillage contains "innovative statements." Forward-looking statements are based on management's expectations and ar subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and public presentation to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, the costs associated with our research, development, manufacturing and other activities, the deal and results of preclinical and clinical studies of our product candidates, difficulties or delays in obtaining regulatory approvals to market place products resulting from our development efforts, our trust on our strategic partners and licensees and other key parties for the successful evolution, manufacturing and commercialization of products, the adequacy of our working capital resources and the availableness of additional funding, patent protection and third-party intellectual property claims relating to our and any partner's product candidates, the timing, scope, cost and outcome of legal and patent office proceeding concerning our NF-?B patent portfolio, the potential attainment of or other strategic transaction regarding the minority stockholders' interests in our 80%-owned underling, ARIAD Gene Therapeutics, Inc., future capital needs, risks related to key employees, markets, economical conditions, prices, reimbursement rates and competition, and other factors elaborate in the Company's public filings with the U.S. Securities and Exchange Commission. The selective information contained in this iron out release is believed to be stream as of the date of original issue. The Company does not signify to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as compulsory by law.
http://www.ariad.com
More info
Subscribe to:
Posts (Atom)